Equitec Proprietary Markets’s Arbutus Biopharma ABUS Stock Holding History

Equitec Proprietary Markets’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$454K	Buy	+95,000	New	+$458K	0.11%	29

Other funds holding ABUS

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Carrera Capital Advisors Troy, Michigan $705M AUM 12.86% 1-Year Est. Return

Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Financiere des Professionnels Montreal, Quebec, Canada $1.75B AUM 28.24% 1-Year Est. Return

KAM

Kazazian Asset Management Fort Lauderdale, Florida $115M AUM 9.41% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Equitec Proprietary Markets's ABUS Position: Q3 2026 in Review

Equitec Proprietary Markets opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 95,000 shares worth $454K. The stake represents 0.11% of the portfolio and ranks #29 among its holdings.

53 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

Equitec Proprietary Markets held 95,000 shares of Arbutus Biopharma worth $454K as of Q3 2026.
Arbutus Biopharma was a new Equitec Proprietary Markets position in Q3 2026.
Arbutus Biopharma made up 0.11% of Equitec Proprietary Markets's portfolio in Q3 2026, its #29 holding.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Equitec Proprietary Markets's 13F filing for Q3 2026, filed 4 Nov 2026.